Galvus magani ne ga ciwon sukari, abu mai aiki wanda shine vildagliptin, daga ƙungiyar Dhib-4 inhibitors. An yi rajistar allunan ciwon sukari na Galvus a Rasha tun daga 2009. Suna samar da Novartis Pharma (Switzerland).
Allunan Galvus don kamuwa da cuta daga ƙungiyar masu hana DPP-4 - abu mai aiki mai suna Vildagliptin
An yi rajista Galvus don kula da marasa lafiya da ke dauke da ciwon sukari na 2. Ana iya amfani dashi azaman magani guda ɗaya, kuma tasirinsa zai cika sakamakon abinci da motsa jiki. Hakanan za'a iya amfani da kwayoyin cutar ciwon sukari na Galvus a hade tare da:
- metformin (siofor, glucophage);
- Kalaman sulfonylurea (kar a yi wannan!);
- thiazolinediones;
- insulin
Fom ɗin saki
Tsarin magunguna Galvus (vildagliptin) - Allunan 50m.
Galvus Allunan sashi
Matsakaicin adadin Galvus a matsayin monotherapy ko tare da haɗin kai tare da metformin, thiazolinediones ko insulin - sau 2 a rana, 50 MG, safe da maraice, ba tare da la'akari da yawan abinci ba. Idan an tsara mai haƙuri akan kwayar 1 of 50 MG kowace rana, to dole ne a sha da safe.
Vildagliptin - kayan aiki na miyagun ƙwayoyi don ciwon sukari Galvus - ƙodan ya keɓe shi, amma a cikin hanyar metabolites marasa aiki. Sabili da haka, a matakin farko na cin nasara na koda, ba a buƙatar canza sashi na maganin ba.
Idan akwai mummunan keta ayyukan hanta (ALT ko enzymes enzymes 2.5 sau sama da babba na al'ada), to ya kamata a tsara Galvus da taka tsantsan. Idan mai haƙuri ya bunkasa jaundice ko wasu gunaguni na hanta sun bayyana, ya kamata a dakatar da maganin ta vildagliptin nan da nan.
Ga masu ciwon sukari shekara 65 da mazan su - kashi na Galvus baya canzawa idan babu alamun cutar sankara. Babu bayanai game da amfani da wannan maganin cutar sankara a yara da matasa masu shekaru 18 da haihuwa. Sabili da haka, ba a ba da shawarar yin shi ga marasa lafiya na wannan rukunin mutanen ba.
Rage tasirin sukari na vildagliptin
An yi nazarin tasirin rage sukari na vildagliptin a cikin rukuni na marasa lafiya 354. Ya juya ga cewa maganin galvus monotherapy a cikin makonni 24 ya haifar da raguwar yawan glucose na jini a cikin wadancan marasa lafiyar da basu yi maganin ciwon suga na 2 ba. Gididdigar haemoglobin su ta ragu da 0.4-0.8%, kuma a cikin ƙungiyar placebo - da 0.1%.
Wani binciken ya kwatanta tasirin vildagliptin da metformin, mafi kyawun maganin cutar sankara (siofor, glucophage). Wannan binciken ya haɗa da marasa lafiya waɗanda kwanan nan sun kamu da cutar sukari ta 2, kuma ba a yi musu magani ba a da.
Ya juya ya nuna cewa galvus a cikin alamomi masu yawa waɗanda ba su da ƙasa da metformin. Bayan makonni 52 (shekara ɗaya na jiyya) a cikin marasa lafiya suna shan galvus, matakin glycated hemoglobin ya ragu da matsakaicin 1.0%. A cikin ƙungiyar metformin, an rage shi da 1.4%. Bayan shekaru 2, lambobin sun kasance iri ɗaya.
Bayan makonni 52 na shan allunan, ya juya cewa tasirin nauyin jikin mutum a cikin rukuni na vildagliptin da metformin kusan iri ɗaya ne.
Mafi kyawun haƙuri ana yarda da Galvus fiye da metformin (Siofor). Sakamakon sakamako na jijiyoyi a cikin hanji na hanji ke ci gaba da yawaita akai-akai. Saboda haka, kayan hukuma na Rashanci na zamani da aka amince da su don maganin cututtukan type 2 suna ba ku damar fara jiyya tare da galvus, tare da metformin.
Karfe Galvus: vildagliptin + haɗuwa metformin
Galvus Met shine magani mai haɗuwa, 1 kwamfutar hannu wanda ya ƙunshi vildagliptin a cikin kashi 50 MG da metformin a allurai na 500, 850 ko 1000 mg. Rajista a Rasha a cikin Maris 2009. An ba da shawarar yin shi ga marasa lafiya 1 kwamfutar hannu 1 sau 2 a rana.
Galvus Met shine magani na haɗuwa don nau'in ciwon sukari na 2. Ya ƙunshi vildagliptin da metformin. Abubuwa biyu masu aiki a cikin kwamfutar hannu guda ɗaya - dace don amfani da tasiri.
Haɗin vildagliptin da metformin an gane cewa sun dace da maganin cututtukan type 2 na marasa lafiya waɗanda ba sa shan metformin kaɗai. Amfaninta:
- sakamakon rage matakan glucose na jini ya karu, idan aka kwatanta da monotherapy tare da kowane daga cikin kwayoyi;
- aikin sauran kwayoyin beta a cikin samar da insulin ana kiyaye su;
- nauyin jiki a cikin marasa lafiya ba ya ƙaruwa;
- haɗarin cututtukan hypoglycemia, ciki har da mai tsanani, baya ƙaruwa;
- yawan tasirin sakamako na metformin daga ƙwayar gastrointestinal - ya kasance a daidai wannan matakin, baya ƙaruwa.
Nazarin ya tabbatar da cewa shan Galvus Met yana da tasiri kamar ɗaukar allunan guda biyu daban-daban tare da metformin da vildagliptin. Amma idan kuna buƙatar ɗaukar kwamfutar hannu guda ɗaya kawai, to, ya fi dacewa kuma magani ya fi tasiri. Domin yana da ƙarancin cewa mai haƙuri zai manta ko ya rikitar da wani abu.
An gudanar da nazari - idan aka kwatanta da maganin cutar sankara tare da Galvus Met tare da wani makirci na gama gari: metformin + sulfonylureas. An ba da maganin Sulfonylureas ga marasa lafiya da masu ciwon sukari waɗanda suka gano Metformin shi kadai ya isa.
Nazarin ya kasance babba-sikeli. Fiye da marasa lafiya 1300 a cikin rukuni biyu sun halarci wannan. Tsawon Lokaci - shekara 1. Ya juya cewa a cikin marasa lafiya suna shan vildagliptin (50 mg sau 2 a rana) tare da metformin, matakan glucose na jini sun ragu har ma da waɗanda suka dauki glimepiride (6 mg 1 lokaci ɗaya kowace rana).
Babu wani bambance-bambance masu mahimmanci a cikin sakamako don rage yawan sukari na jini. A lokaci guda, marasa lafiya a cikin rukuni na miyagun ƙwayoyi na Galvus Met sun ɗanɗano jinin hailawa sau 10 ƙasa da waɗanda ba a kula da su tare da glimepiride tare da metformin. Babu wani lamunin rashin lafiya mai tsanani a cikin marasa lafiya da ke shan Galvus Met na tsawon shekara.
Yadda ake Amfani da Magungunan Ciwon Ciwon Galvus Tare da insulin
Galvus shine farkon maganin maganin ciwon sukari a cikin rukunin inhibitor na DPP-4, wanda aka yi rajista don haɗuwa da insulin. A matsayinka na mai mulki, an tsara shi idan ba zai yiwu a sarrafa nau'in ciwon sukari guda 2 da kyau tare da maganin basal kadai ba, wato, “insulin” tsawo.
Nazarin 2007 ya kimanta inganci da amincin ƙara galvus (50 mg sau 2 a rana) a kan placebo. Marasa lafiya sun halarci waɗanda suka kasance a cikin matakan hawan jini mai narkewa (7.5-1%) a kan injections na “matsakaici” insulin tare da tsaka tsaki na Hagedorn protramine (NPH) a sashi na sama da raka'a 30 a rana.
Marasa lafiya 144 sun karɓi galvus tare da allurar insulin, marasa lafiya 152 da ke da nau'in ciwon sukari na 2 sun karɓi placebo a tushen allurar insulin. A cikin rukunin vildagliptin, matsakaicin matakin gemoclobin hemoglobin ya ragu da 0,5%. A cikin rukunin placebo, ta kashi 0.2%. A cikin marasa lafiya da suka girmi shekaru 65, alamu sunfi kyau - ragin 0.7% akan asalin galvus da 0.1% a sakamakon shan placebo.
Bayan ƙara galvus zuwa insulin, haɗarin hypoglycemia yana raguwa sosai, idan aka kwatanta da ilimin kwantar da hankali, injections na "matsakaita" NPH-insulin. A cikin rukunin vildagliptin, jimlar adadin hypoglycemia ya kasance 113, a cikin rukunin placebo - 185. Bugu da ƙari, ba a lura da yanayin guda ɗaya na mummunan hypoglycemia tare da maganin cutar sankara na vildagliptin. Akwai 6 irin wannan aukuwa a cikin kungiyar placebo.
Side effects
Gabaɗaya, galvus magani ne mai lafiya. Nazarin sun tabbatar da cewa maganin warkewar cututtukan fata na nau'in 2 tare da wannan magani baya kara haɗarin cutar cututtukan zuciya, matsalolin hanta, ko raunin tsarin garkuwar jiki. Shan vildagliptin (kayan aiki mai aiki a cikin allunan galvus) baya kara nauyi a jiki.
Idan aka kwatanta da wakilai masu rage zafin jini na gargajiya, kazalika da placebo, galvus baya kara hadarin cututtukan farji. Yawancin cututtukan ta suna da laushi da wucin gadi. Da wuya a lura:
- aikin hanta mai rauni (gami da cutar hepatitis);
- angioedema.
Halin wadannan sakamako masu illa shine daga 1/1000 zuwa 1/10 000 marasa lafiya.
Maganin ciwon sukari na Galvus: contraindications
Contraindications zuwa saduwa da Allunan daga ciwon sukari Galvus:
- nau'in ciwon sukari na 1;
- ciki da lactation;
- mai ciwon sukari mai ciwon sukari;
- rashin hankali ga abubuwan da ke cikin miyagun ƙwayoyi.
